Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Abstract

Available data on switching from originator infliximab to CT-P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes. However, monitoring of such patients, especially in the early phase after switching, is important given the possibility that rare side effects might occur, as illustrated here.
Original languageEnglish
JournalClinical Case Reports
DOIs
Publication statusPublished - 2019

Cite this